249 related articles for article (PubMed ID: 29596222)
1. A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis.
Benjamin DK; Kaufman DA; Hope WW; Smith PB; Arrieta A; Manzoni P; Kovanda LL; Lademacher C; Isaacson B; Jednachowski D; Wu C; Kaibara A; Walsh TJ
Pediatr Infect Dis J; 2018 Oct; 37(10):992-998. PubMed ID: 29596222
[TBL] [Abstract][Full Text] [Related]
2. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD; Lyseng-Williamson KA; Scott LJ
Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Echinocandins for the Treatment of Invasive Candidiasis in Children: A Meta-analysis.
Tsekoura M; Ioannidou M; Pana ZD; Haidich AB; Antachopoulos C; Iosifidis E; Kolios G; Roilides E
Pediatr Infect Dis J; 2019 Jan; 38(1):42-49. PubMed ID: 29596219
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind trial investigating the efficacy of caspofungin versus amphotericin B deoxycholate in the treatment of invasive candidiasis in neonates and infants younger than 3 months of age.
Kim J; Nakwa FL; Araujo Motta F; Liu H; Dorr MB; Anderson LJ; Kartsonis N
J Antimicrob Chemother; 2020 Jan; 75(1):215-220. PubMed ID: 31586424
[TBL] [Abstract][Full Text] [Related]
5. In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin.
Lewis RE; Wiederhold NP; Prince RA; Kontoyiannis DP
J Antimicrob Chemother; 2006 Feb; 57(2):288-93. PubMed ID: 16387749
[TBL] [Abstract][Full Text] [Related]
6. Exposure-Response Analysis of Micafungin in Neonatal Candidiasis: Pooled Analysis of Two Clinical Trials.
Kovanda LL; Walsh TJ; Benjamin DK; Arrieta A; Kaufman DA; Smith PB; Manzoni P; Desai AV; Kaibara A; Bonate PL; Hope WW
Pediatr Infect Dis J; 2018 Jun; 37(6):580-585. PubMed ID: 29762386
[TBL] [Abstract][Full Text] [Related]
7. Antifungal therapy and outcomes in infants with invasive Candida infections.
Ascher SB; Smith PB; Watt K; Benjamin DK; Cohen-Wolkowiez M; Clark RH; Benjamin DK; Moran C
Pediatr Infect Dis J; 2012 May; 31(5):439-43. PubMed ID: 22189522
[TBL] [Abstract][Full Text] [Related]
8. Continuously infused amphotericin B deoxycholate for primary treatment of invasive fungal disease in acute myeloid leukaemia.
Rothenbühler C; Held U; Manz MG; Schanz U; Gerber B
Hematol Oncol; 2018 Apr; 36(2):471-480. PubMed ID: 29431860
[TBL] [Abstract][Full Text] [Related]
9. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate.
Bekersky I; Fielding RM; Dressler DE; Lee JW; Buell DN; Walsh TJ
Antimicrob Agents Chemother; 2002 Mar; 46(3):834-40. PubMed ID: 11850269
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection.
Lepak AJ; Zhao M; Berkow EL; Lockhart SR; Andes DR
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584152
[No Abstract] [Full Text] [Related]
11. Advances in the treatment of invasive neonatal candidiasis.
Botero-Calderon L; Benjamin DK; Cohen-Wolkowiez M
Expert Opin Pharmacother; 2015 May; 16(7):1035-48. PubMed ID: 25842986
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, prospective study of caspofungin vs. amphotericin B for the treatment of invasive candidiasis in newborn infants.
Mohamed WA; Ismail M
J Trop Pediatr; 2012 Feb; 58(1):25-30. PubMed ID: 21355042
[TBL] [Abstract][Full Text] [Related]
13. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.
Queiroz-Telles F; Berezin E; Leverger G; Freire A; van der Vyver A; Chotpitayasunondh T; Konja J; Diekmann-Berndt H; Koblinger S; Groll AH; Arrieta A;
Pediatr Infect Dis J; 2008 Sep; 27(9):820-6. PubMed ID: 18679151
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis.
Lestner JM; Howard SJ; Goodwin J; Gregson L; Majithiya J; Walsh TJ; Jensen GM; Hope WW
Antimicrob Agents Chemother; 2010 Aug; 54(8):3432-41. PubMed ID: 20439615
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.
Bekersky I; Fielding RM; Dressler DE; Lee JW; Buell DN; Walsh TJ
Antimicrob Agents Chemother; 2002 Mar; 46(3):828-33. PubMed ID: 11850268
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis.
Wiederhold NP; Tam VH; Chi J; Prince RA; Kontoyiannis DP; Lewis RE
Antimicrob Agents Chemother; 2006 Feb; 50(2):469-73. PubMed ID: 16436698
[TBL] [Abstract][Full Text] [Related]
17. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.
Walsh TJ; Goodman JL; Pappas P; Bekersky I; Buell DN; Roden M; Barrett J; Anaissie EJ
Antimicrob Agents Chemother; 2001 Dec; 45(12):3487-96. PubMed ID: 11709329
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of micafungin versus liposomal amphotericin B (LAmB) for treating patients with candidaemia and invasive candidiasis (IC) in Turkey.
Neoh CF; Senol E; Kara A; Dinleyici EC; Turner SJ; Kong DCM
Eur J Clin Microbiol Infect Dis; 2018 Sep; 37(9):1777-1784. PubMed ID: 29959610
[TBL] [Abstract][Full Text] [Related]
19. Invasive fungal infections in newborns and current management strategies.
Hundalani S; Pammi M
Expert Rev Anti Infect Ther; 2013 Jul; 11(7):709-21. PubMed ID: 23829639
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and tissue distribution after intravenous administration of a single dose of amphotericin B cochleates, a new lipid-based delivery system.
Segarra I; Movshin DA; Zarif L
J Pharm Sci; 2002 Aug; 91(8):1827-37. PubMed ID: 12115810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]